Published: 15 April 2016

Committees

Comments on Agenda Items for the 55th meeting of the Medicines Classification Committee to be held on 3 May 2016

A total of 22 submissions commenting on agenda items for the 55th meeting (PDF 29.2 MB, 305 pages) were received.

One comment was received on objections to recommendations made at the 54th MCC meeting (agenda item 5.1).

Nine comments were received regarding the proposed reclassification of selected oral contraceptives as a restricted medicine (agenda item 5.1.1).

Four comments were received on the updating of the guidance document titled ‘How to change the legal classification of a medicine in New Zealand’ to include the publication of additional information submitted in objections (agenda item 5.2.1).

One comment was received on the updating of the Medicines Classification Committee Handbook to include a Deputy Chair (agenda item 5.2.2).

Two comments were received on the review of tramadol and codeine reclassification (agenda item 5.2.3).

One comment was received on the change in classification wording of benzydamine from general sales medicine for topical and external use to general sales medicine for oromucosal and topical use (agenda item 5.2.4).

One comment was received on the proposed amendment to classification wording of lignocaine (agenda item 5.2.5).

Two comments were received on the proposed classification of alcohol in hand sanitisers (agenda item 6.1).

Five comments were received on the proposed reclassification of adapalene as a prescription medicine except in medicines containing not more than 1 mg/g and when supplied in a pack not more than 30 g by a pharmacist (agenda item 6.2).

Nine comments were received regarding the proposed reclassification of albendazole to pharmacy-only medicine (agenda item 6.3).

Three comments were received on the proposed extension of the general sales medicine classification of loratadine to 10 days’ supply (agenda item 6.4).

Five comments were received regarding the proposed change in classification wording of lansoprazole, promethazine, sumatriptan, ibuprofen, omeprazole, pantoprazole, opium, pholcodine and ranitidine (agenda item 6.5).

One comment was received on the proposed reclassification of esomeprazole (agenda item 8.2.1.a).

One comment was received on the proposed reclassification of hydrocortisone (agenda item 8.2.1.b).

One comment was received on the proposed reclassification of levocetirizine (agenda item 8.2.1.c).

Six submissions commenting on the proposed reclassification of naloxone were received (agenda item 8.2.1.d).